Study of Combination Therapy With SYR-322

Summary

To determine the efficacy and safety of SYR-322 (alogliptin) 25-mg, once daily (QD), in patients with diabetes when used in combination with insulin.

Timeline

Start

2012-02

Primary completion

2013-03

Completion

2013-03

Outcome

Met primary endpoint

paper The point estimate (95% confidence interval) intergroup difference was -0.66% ([-0.824%, -0.503%]). PMID 25190226 ↗

Publications

• Kaku K, Mori M, Kanoo T, Katou M, Seino Y. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opin Pharmacother. 2014 Oct;15(15):2121-30. doi: 10.1517/14656566.2014.956722. Epub 2014 Sep 5.

Drugs

Indications